For research and educational purposes only. Not medical advice.

Icatibant Reference

Educational, not medical advice reference for Icatibant: Immune; regulatory status, evidence posture, source review, and schedule notes. Also kn…

Reference summary

Icatibant is a label-verified bradykinin B2 receptor antagonist with FDA Phase 3 evidence in acute attacks of hereditary angioedema. pepSmart surfaces label-reference content only.

Regulatory and posture

Categories
Immune
Aliases
Firazyr, JE 049, HOE 140, Bradykinin B2 antagonist
Evidence posture
human - Approved for an extremely narrow rare-disease indication (acute HAE attacks). Not a chronic-use or wellness drug. Self-administration in HAE is patient-training-dependent; clinicians remain involved per label. Laryngeal attacks should be managed in a healthcare setting.
Regulatory status
FDA-approved prescription medication (Firazyr). Initial US approval 2011. Indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults aged 18 years or older. Synthetic decapeptide selective bradykinin B2 receptor antagonist. Prescription-only.
Content review status
label verified

Selected public sources

Related tools